By Press release submission |
Jun 7, 2020
For people diagnosed with metastatic HER2-positive breast cancer that has spread to the brain, adding Tukysa (chemical name: tucatinib) to the standard treatment regimen of Herceptin (chemical name: trastuzumab) and Xeloda (chemical name: capecitabine) reduced the risk that the brain lesions would grow and also improved survival, according to an exploratory analysis of results from the HER2CLIMB trial.